SlideShare uma empresa Scribd logo
1 de 3
Lung parenchymal
involvement in RRP




     Questions
Questions: Lung parenchymal disease in
               RRP - cases
#1 – Would clinical course be different 15 years on?
#2 - Did Cidofovir help to control his disease, or predispose
  to malignancy?
#3 – Would you:
       Wait
       Gardasil?
       Inteferon?
#4- How to monitor:
       MRI or CT?
       Cytology or just biospies?
       Interferon Yes/No?
Questions: Lung parenchymal disease in RRP

1. Who in audience has had experience of lung disease in RRP?
   Yes/No

2. What treatment options have been tried?
   Interferon,
   Cidofovir,
   Other?

3. Should we be concerned about malignant potential of cidofovir in a
   disease with such a poor outlook? Yes/No

4. What monitoring?
   Scans, Biopsies, Cytology, Lung function?

Mais conteúdo relacionado

Semelhante a Lung parenchymal involvement in rrp mini for seth

GFATM training for nurses
GFATM training for nursesGFATM training for nurses
GFATM training for nursesanjalatchi
 
GFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptxGFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptxnaveenithkrishnan
 
Mycophenalate.pptx
Mycophenalate.pptxMycophenalate.pptx
Mycophenalate.pptxdrperumal
 
covid-9 clinical_management_and_treatment.pptx
covid-9 clinical_management_and_treatment.pptxcovid-9 clinical_management_and_treatment.pptx
covid-9 clinical_management_and_treatment.pptxsergeipee
 
Covid -19/ Sars-Cov-2
Covid -19/ Sars-Cov-2Covid -19/ Sars-Cov-2
Covid -19/ Sars-Cov-2Wazeed Basha
 
2018 09-20 biomarkers for post-transplant immune injury
2018 09-20 biomarkers for post-transplant immune injury2018 09-20 biomarkers for post-transplant immune injury
2018 09-20 biomarkers for post-transplant immune injuryMaarten Naesens
 
HEALTH SCREENING SERVICES IN COMMUNITY PHARMACY.pptx
HEALTH SCREENING SERVICES IN COMMUNITY PHARMACY.pptxHEALTH SCREENING SERVICES IN COMMUNITY PHARMACY.pptx
HEALTH SCREENING SERVICES IN COMMUNITY PHARMACY.pptxsnehavikhe
 
Autoimmune ILD.pptx
Autoimmune ILD.pptxAutoimmune ILD.pptx
Autoimmune ILD.pptxMarwa Besar
 
02.02 adult art initiation gsn
02.02 adult  art initiation gsn02.02 adult  art initiation gsn
02.02 adult art initiation gsnDavid Ngogoyo
 
Pharmacovigilance overview shraddha
Pharmacovigilance  overview shraddhaPharmacovigilance  overview shraddha
Pharmacovigilance overview shraddhaDr. Shraddha Bhange
 
what every PCP needs to know about Hepatitis C_Dr. Paul Pinto
what every PCP needs to know about Hepatitis C_Dr. Paul Pintowhat every PCP needs to know about Hepatitis C_Dr. Paul Pinto
what every PCP needs to know about Hepatitis C_Dr. Paul PintoHealthyColoradan
 
Awareness of the people about the cause of erysipelas and their treatments
Awareness of the people about the cause of erysipelas and their treatmentsAwareness of the people about the cause of erysipelas and their treatments
Awareness of the people about the cause of erysipelas and their treatmentsBRNSSPublicationHubI
 
Herbs acting as immune boosters in covid 19
Herbs acting as immune boosters in covid 19Herbs acting as immune boosters in covid 19
Herbs acting as immune boosters in covid 19Priyansha Singh
 
CAP 2010 Guidelines
CAP 2010 GuidelinesCAP 2010 Guidelines
CAP 2010 Guidelinescap_0009
 

Semelhante a Lung parenchymal involvement in rrp mini for seth (20)

GFATM training for nurses
GFATM training for nursesGFATM training for nurses
GFATM training for nurses
 
GFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptxGFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptx
 
Examining the IPF Patient’s Journey to Diagnosis, Appropriate Therapy, and Ov...
Examining the IPF Patient’s Journey to Diagnosis, Appropriate Therapy, and Ov...Examining the IPF Patient’s Journey to Diagnosis, Appropriate Therapy, and Ov...
Examining the IPF Patient’s Journey to Diagnosis, Appropriate Therapy, and Ov...
 
Mycophenalate.pptx
Mycophenalate.pptxMycophenalate.pptx
Mycophenalate.pptx
 
Biomarkers for Scleroderma
Biomarkers for SclerodermaBiomarkers for Scleroderma
Biomarkers for Scleroderma
 
covid-9 clinical_management_and_treatment.pptx
covid-9 clinical_management_and_treatment.pptxcovid-9 clinical_management_and_treatment.pptx
covid-9 clinical_management_and_treatment.pptx
 
Covid -19/ Sars-Cov-2
Covid -19/ Sars-Cov-2Covid -19/ Sars-Cov-2
Covid -19/ Sars-Cov-2
 
2018 09-20 biomarkers for post-transplant immune injury
2018 09-20 biomarkers for post-transplant immune injury2018 09-20 biomarkers for post-transplant immune injury
2018 09-20 biomarkers for post-transplant immune injury
 
HEALTH SCREENING SERVICES IN COMMUNITY PHARMACY.pptx
HEALTH SCREENING SERVICES IN COMMUNITY PHARMACY.pptxHEALTH SCREENING SERVICES IN COMMUNITY PHARMACY.pptx
HEALTH SCREENING SERVICES IN COMMUNITY PHARMACY.pptx
 
Assignment on HIV and AIDS
Assignment on HIV and AIDSAssignment on HIV and AIDS
Assignment on HIV and AIDS
 
Autoimmune ILD.pptx
Autoimmune ILD.pptxAutoimmune ILD.pptx
Autoimmune ILD.pptx
 
02.02 adult art initiation gsn
02.02 adult  art initiation gsn02.02 adult  art initiation gsn
02.02 adult art initiation gsn
 
Pharmacovigilance overview shraddha
Pharmacovigilance  overview shraddhaPharmacovigilance  overview shraddha
Pharmacovigilance overview shraddha
 
Nurses at the Forefront of the Continuing Success Story of Immunotherapy in N...
Nurses at the Forefront of the Continuing Success Story of Immunotherapy in N...Nurses at the Forefront of the Continuing Success Story of Immunotherapy in N...
Nurses at the Forefront of the Continuing Success Story of Immunotherapy in N...
 
Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: ...
Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: ...Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: ...
Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: ...
 
what every PCP needs to know about Hepatitis C_Dr. Paul Pinto
what every PCP needs to know about Hepatitis C_Dr. Paul Pintowhat every PCP needs to know about Hepatitis C_Dr. Paul Pinto
what every PCP needs to know about Hepatitis C_Dr. Paul Pinto
 
Non-IPF ILDs
Non-IPF ILDsNon-IPF ILDs
Non-IPF ILDs
 
Awareness of the people about the cause of erysipelas and their treatments
Awareness of the people about the cause of erysipelas and their treatmentsAwareness of the people about the cause of erysipelas and their treatments
Awareness of the people about the cause of erysipelas and their treatments
 
Herbs acting as immune boosters in covid 19
Herbs acting as immune boosters in covid 19Herbs acting as immune boosters in covid 19
Herbs acting as immune boosters in covid 19
 
CAP 2010 Guidelines
CAP 2010 GuidelinesCAP 2010 Guidelines
CAP 2010 Guidelines
 

Lung parenchymal involvement in rrp mini for seth

  • 2. Questions: Lung parenchymal disease in RRP - cases #1 – Would clinical course be different 15 years on? #2 - Did Cidofovir help to control his disease, or predispose to malignancy? #3 – Would you: Wait Gardasil? Inteferon? #4- How to monitor: MRI or CT? Cytology or just biospies? Interferon Yes/No?
  • 3. Questions: Lung parenchymal disease in RRP 1. Who in audience has had experience of lung disease in RRP? Yes/No 2. What treatment options have been tried? Interferon, Cidofovir, Other? 3. Should we be concerned about malignant potential of cidofovir in a disease with such a poor outlook? Yes/No 4. What monitoring? Scans, Biopsies, Cytology, Lung function?